Despite the improved pathological complete response rate in HER2‐positive breast cancer patients with neoadjuvant dual HER2 blockade, it would be desirable to identify patients exquisitely responsive to single agent trastuzumab to minimize or avoid overtreatment. This evidence concerns the gene ERBB2 and breast cancer.